Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epetraborole - Pfizer

Next Previous
Drug Profile

Epetraborole - Pfizer

Alternative Names: AN-3365; AN2-501971; BRII-658; GSK '052; GSK-052; GSK-2251052

Latest Information Update: 11 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anacor Pharmaceuticals
  • Developer AN2 Therapeutics; Anacor Pharmaceuticals; GlaxoSmithKline
  • Class 2 ring heterocyclic compounds; Anti-infectives; Antibacterials; Benzene derivatives; Organic boron compounds; Small molecules; Urinary anti-infective agents
  • Mechanism of Action Leucyl-tRNA synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nontuberculous mycobacterium infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Nontuberculous mycobacterium infections
  • Phase I Melioidosis
  • Suspended Gram-negative infections
  • Discontinued Intra-abdominal infections; Urinary tract infections

Most Recent Events

  • 03 Mar 2026 AN2 Therapeutics announces its intention to receive regulatory clearance to commence a phase II trial for Polycythemia vera (PO)
  • 03 Mar 2026 AN2 Therapeutics plans a phase II trial for Polycythemia vera (PO) in the third quarter of 2026
  • 12 Jan 2026 USFDA approves IND application for epetraborole in Nontuberculous mycobacterium infections

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top